+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endo International Plc (ENDPQ) - Financial and Strategic SWOT Analysis Review

Endo International Plc (ENDPQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Endo International Plc (Endo) is a specialty healthcare company that develops, manufactures, and commercializes various branded pharmaceuticals, generic pharmaceuticals, sterile injectables and other products through its operating companies. It sells generic products in the US in various categories including urology, pain management, orthopedics, endocrinology, central nervous system (CNS) disorders, cancer, cardiovascular diseases, and women’s health. The company offers branded pharmaceuticals for conditions related to urology, orthopedics, endocrine disorders, and pain management. Endo also provides over the counter (OTC) products, which include dermatological products and anti-infectives. The company sells its products through independent wholesale distributors to retailers, government agencies, doctors, clinics, independent retail and specialty pharmacies and independent specialty distributors. Endo is headquartered in Dublin, Ireland.

Endo International Plc Key Recent Developments

  • Mar 06, 2023: ENDO REPORTS FOURTH-QUARTER 2022 FINANCIAL RESULTS
  • Nov 09, 2022: ENDO REPORTS THIRD-QUARTER 2022 FINANCIAL RESULTS
  • Oct 27, 2022: Endo and SMSNA launch app to provide Peyronie's disease self-assessment tool
  • May 05, 2022: ENDO REPORTS FIRST-QUARTER 2022 FINANCIAL RESULTS

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Endo International Plc - Key Facts
  • Endo International Plc - Key Employees
  • Endo International Plc - Key Employee Biographies
  • Endo International Plc - Major Products and Services
  • Endo International Plc - History
  • Endo International Plc - Company Statement
  • Endo International Plc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Endo International Plc - Business Description
  • Business Segment: Branded Pharmaceuticals
  • Overview
  • Performance
  • Business Segment: Generic Pharmaceuticals
  • Overview
  • Performance
  • Business Segment: International Pharmaceuticals
  • Overview
  • Performance
  • Business Segment: Sterile Injectables
  • Overview
  • Performance
  • R&D Overview
  • Endo International Plc - Corporate Strategy
  • Endo International Plc - SWOT Analysis
  • SWOT Analysis - Overview
  • Endo International Plc - Strengths
  • Endo International Plc - Weaknesses
  • Endo International Plc - Opportunities
  • Endo International Plc - Threats
  • Endo International Plc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Endo International Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Endo International Plc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Endo International Plc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Mar 06, 2023: ENDO REPORTS FOURTH-QUARTER 2022 FINANCIAL RESULTS
  • Nov 09, 2022: ENDO REPORTS THIRD-QUARTER 2022 FINANCIAL RESULTS
  • Oct 27, 2022: Endo and SMSNA launch app to provide Peyronie's disease self-assessment tool
  • May 05, 2022: ENDO REPORTS FIRST-QUARTER 2022 FINANCIAL RESULTS
  • Apr 20, 2022: Tennessee Court of appeals orders recusal of trial court judge and vacates default judgment on liability against Endo
  • Mar 03, 2022: Endo launches New Living Our Values Program to recognize outstanding team members
  • Feb 28, 2022: Endo reports fourth-quarter and full-year 2021 financial results
  • Jan 18, 2022: Endo reaches agreement intended to settle Florida governmental opioid cases and claims
  • Jan 11, 2022: Endo Appoints Dr. James P. Tursi as Executive Vice President, Global Research & Development
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Endo International Plc, Key Facts
  • Endo International Plc, Key Employees
  • Endo International Plc, Key Employee Biographies
  • Endo International Plc, Major Products and Services
  • Endo International Plc, History
  • Endo International Plc, Other Locations
  • Endo International Plc, Subsidiaries
  • Endo International Plc, Key Competitors
  • Endo International Plc, Ratios based on current share price
  • Endo International Plc, Annual Ratios
  • Endo International Plc, Interim Ratios
  • Endo International Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Endo International Plc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Endo International Plc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Endo International Plc, Performance Chart (2018 - 2022)
  • Endo International Plc, Ratio Charts
  • Endo International Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Endo International Plc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Amneal Pharmaceuticals Inc
  • Amphastar Pharmaceuticals Inc
  • Fresenius Kabi USA LLC
  • Jazz Pharmaceuticals Plc
  • Revance Therapeutics Inc
  • Hospira Inc
  • Sandoz SpA
  • Mallinckrodt Plc
  • Viatris Inc
  • AbbVie Inc
  • Horizon Therapeutics Plc
  • Takeda Pharmaceutical Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Horizon Therapeutics Plc
  • Hikma Pharmaceuticals Plc
  • AbbVie Inc
  • Amneal Pharmaceuticals Inc
  • Amphastar Pharmaceuticals Inc
  • Fresenius Kabi USA LLC
  • Jazz Pharmaceuticals Plc
  • Revance Therapeutics Inc
  • Teva Pharmaceutical Industries Ltd
  • Aurobindo Pharma Ltd
  • Viatris Inc
  • Eagle Pharmaceuticals Inc
  • Hospira Inc
  • Mallinckrodt Plc
  • Sandoz SpA
  • Vizient Inc
  • Healthtrust Purchasing Group LP